Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Kiniksa Pharmaceuticals Ltd (KNSA)

Kiniksa Pharmaceuticals Ltd (KNSA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 808,643
  • Shares Outstanding, K 69,471
  • Annual Sales, $ 38,540 K
  • Annual Income, $ -157,920 K
  • 60-Month Beta -0.12
  • Price/Sales 21.59
  • Price/Cash Flow N/A
  • Price/Book 5.42
Trade KNSA with:

Options Overview Details

View History
  • Implied Volatility 75.88% ( +16.57%)
  • Historical Volatility 66.57%
  • IV Percentile 23%
  • IV Rank 17.50%
  • IV High 240.09% on 06/15/22
  • IV Low 41.05% on 06/14/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 30
  • Volume Avg (30-Day) 55
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 4,270
  • Open Int (30-Day) 3,795

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 0.38
  • Number of Estimates 3
  • High Estimate 0.77
  • Low Estimate -0.34
  • Prior Year -0.44
  • Growth Rate Est. (year over year) +186.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.63 +20.56%
on 08/01/22
13.75 -15.56%
on 08/05/22
+0.15 (+1.31%)
since 07/19/22
3-Month
7.36 +57.74%
on 06/01/22
13.75 -15.56%
on 08/05/22
+3.43 (+41.93%)
since 05/19/22
52-Week
7.36 +57.74%
on 06/01/22
15.24 -23.84%
on 11/02/21
-0.05 (-0.43%)
since 08/19/21

Most Recent Stories

More News
Wall Street Analysts See an 114% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 113.9% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable,...

KNSA : 11.65 (+0.09%)
Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference

HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in...

KNSA : 11.65 (+0.09%)
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Lags Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 32.56% and 2.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?...

KNSA : 11.65 (+0.09%)
LQDA : 7.44 (-3.38%)
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

– ARCALYST® (rilonacept) net revenue of $27.0 million in Q2 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Upfront...

KNSA : 11.65 (+0.09%)
Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab

– Kiniksa to receive $100 million in upfront and near-term payments – – Kiniksa is eligible to receive development and commercial milestones as well as...

KNSA : 11.65 (+0.09%)
Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022

HAMILTON, Bermuda, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and...

KNSA : 11.65 (+0.09%)
Kiniksa Pharmaceuticals, Ltd. (KNSA) Upgraded to Buy: Here's What You Should Know

Kiniksa Pharmaceuticals, Ltd. (KNSA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

KNSA : 11.65 (+0.09%)
Cytokinetics (CYTK) Soars 6.1%: Is Further Upside Left in the Stock?

Cytokinetics (CYTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term....

CYTK : 50.68 (-0.24%)
KNSA : 11.65 (+0.09%)
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates

Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 30.77% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

KNSA : 11.65 (+0.09%)
ETON : 2.33 (-2.92%)
Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

– ARCALYST® (rilonacept) net revenue of $22.2 million in Q1 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Cash...

KNSA : 11.65 (+0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Kiniksa Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa Pharmaceuticals Ltd. is based in Massachusetts,...

See More

Key Turning Points

3rd Resistance Point 12.41
2nd Resistance Point 12.21
1st Resistance Point 11.92
Last Price 11.65
1st Support Level 11.43
2nd Support Level 11.23
3rd Support Level 10.94

See More

52-Week High 15.24
Fibonacci 61.8% 12.23
Last Price 11.65
Fibonacci 50% 11.30
Fibonacci 38.2% 10.37
52-Week Low 7.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar